{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T22:12:46Z","timestamp":1785017566241,"version":"3.55.0"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajconline.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Cardiology"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.amjcard.2020.03.034","type":"journal-article","created":{"date-parts":[[2020,4,10]],"date-time":"2020-04-10T11:03:41Z","timestamp":1586516621000},"page":"29-36","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Real-World Direct Comparison of the Effectiveness and Safety of Apixaban, Dabigatran, Rivaroxaban, and Warfarin in Medicare Beneficiaries With Atrial Fibrillation"],"prefix":"10.1016","volume":"126","author":[{"given":"Lanting","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria M.","family":"Brooks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2265-0162","authenticated-orcid":false,"given":"Nancy W.","family":"Glynn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6460-6779","authenticated-orcid":false,"given":"Yuting","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samir","family":"Saba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inmaculada","family":"Hernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjcard.2020.03.034_bib0001","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1016\/j.amjcard.2017.07.092","article-title":"Comparison of the effectiveness and safety of apixaban, dabigatran, rivaroxaban, and warfarin in newly diagnosed atrial fibrillation","volume":"120","author":"Hernandez","year":"2017","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjcard.2020.03.034_bib0002","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1160\/TH12-02-0093","article-title":"An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation","volume":"108","author":"Mantha","year":"2012","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.amjcard.2020.03.034_bib0003","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.jacc.2012.03.019","article-title":"Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation","volume":"60","author":"Lip","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2020.03.034_bib0004","first-page":"330","article-title":"Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis","volume":"31","author":"Harenberg","year":"2012","journal-title":"Int Angiol"},{"key":"10.1016\/j.amjcard.2020.03.034_bib0005","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1161\/STROKEAHA.116.016275","article-title":"Rivaroxaban versus dabigatran or warfarin in real-world studies of stroke prevention in atrial fibrillation: systematic review and meta-analysis","volume":"48","author":"Bai","year":"2017","journal-title":"Stroke"},{"key":"10.1016\/j.amjcard.2020.03.034_bib0006","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/joim.12683","article-title":"Standard and reduced doses of dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation: a nationwide cohort study","volume":"283","author":"Staerk","year":"2018","journal-title":"J Intern Med"},{"key":"10.1016\/j.amjcard.2020.03.034_bib0007","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/S1474-4422(13)70255-2","article-title":"Secondary stroke prevention","volume":"13","author":"Hankey","year":"2014","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.amjcard.2020.03.034_bib0008","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1111\/jgs.15956","article-title":"Comparisons between oral anticoagulants among older nonvalvular atrial fibrillation patients","volume":"67","author":"Deitelzweig","year":"2019","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.amjcard.2020.03.034_bib0009","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.ijcard.2015.11.084","article-title":"Relative efficacy and safety of non-Vitamin K oral anticoagulants for non-valvular atrial fibrillation: network meta-analysis comparing apixaban, dabigatran, rivaroxaban and edoxaban in three patient subgroups","volume":"204","author":"Lip","year":"2016","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.amjcard.2020.03.034_bib0010","doi-asserted-by":"crossref","first-page":"e91398","DOI":"10.1371\/journal.pone.0091398","article-title":"Consistency of safety and efficacy of new oral anticoagulants across subgroups of patients with atrial fibrillation","volume":"9","author":"Lega","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.amjcard.2020.03.034_bib0011","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.amjcard.2018.03.012","article-title":"Effectiveness and safety of direct oral anticoagulants and warfarin, stratified by stroke risk in patients with atrial fibrillation","volume":"122","author":"Hernandez","year":"2018","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjcard.2020.03.034_bib0012","unstructured":"Center for Medicare and Medicaid Services. Chronic Conditions Data Warehouse: condition category 2019. Available at:https:\/\/www2.ccwdata.org\/web\/guest\/condition-categories. Accessed April 23, 2020."},{"key":"10.1016\/j.amjcard.2020.03.034_bib0013","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1001\/jamainternmed.2014.5398","article-title":"Risk of bleeding with dabigatran in atrial fibrillation","volume":"175","author":"Hernandez","year":"2015","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.amjcard.2020.03.034_bib0014","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s40256-016-0189-9","article-title":"Comparing stroke and bleeding with rivaroxaban and dabigatran in atrial fibrillation: analysis of the US Medicare Part D data","volume":"17","author":"Hernandez","year":"2017","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.amjcard.2020.03.034_bib0015","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1001\/jama.2015.10725","article-title":"Assessment of the CHA2DS2-VASc score in predicting ischemic stroke, thromboembolism, and death in patients with heart failure with and without atrial fibrillation","volume":"314","author":"Melgaard","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.amjcard.2020.03.034_bib0016","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1002\/clc.22435","article-title":"The HAS-BLED score for predicting major bleeding risk in anticoagulated patients with atrial fibrillation: a systematic review and meta-analysis","volume":"38","author":"Zhu","year":"2015","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.amjcard.2020.03.034_bib0017","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/S1474-4422(10)70274-X","article-title":"Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial","volume":"9","author":"Diener","year":"2010","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.amjcard.2020.03.034_bib0018","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/S1474-4422(12)70092-3","article-title":"Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trial","volume":"11","author":"Easton","year":"2012","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.amjcard.2020.03.034_bib0019","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/S1474-4422(12)70042-X","article-title":"Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF","volume":"11","author":"Hankey","year":"2012","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.amjcard.2020.03.034_bib0020","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1161\/STROKEAHA.117.017474","article-title":"Effectiveness and safety of apixaban, dabigatran, and rivaroxaban versus warfarin in patients with nonvalvular atrial fibrillation and previous stroke or transient ischemic attack","volume":"48","author":"Coleman","year":"2017","journal-title":"Stroke"},{"key":"10.1016\/j.amjcard.2020.03.034_bib0021","first-page":"958","article-title":"Adherence to rivaroxaban, dabigatran, and apixaban for stroke prevention for newly diagnosed and treatment-naive atrial fibrillation patients: an update using 2013-2014 data","volume":"23","author":"Brown","year":"2017","journal-title":"J Manag Care Spec Pharm"}],"container-title":["The American Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914920303234?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914920303234?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T06:33:22Z","timestamp":1757572402000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002914920303234"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":21,"alternative-id":["S0002914920303234"],"URL":"https:\/\/doi.org\/10.1016\/j.amjcard.2020.03.034","relation":{},"ISSN":["0002-9149"],"issn-type":[{"value":"0002-9149","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-World Direct Comparison of the Effectiveness and Safety of Apixaban, Dabigatran, Rivaroxaban, and Warfarin in Medicare Beneficiaries With Atrial Fibrillation","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjcard.2020.03.034","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}